ClinicalTrials.gg
Active, not recruitingNCT06432296Updated Aug 20, 2026

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

A Phase 3 interventional study of M701 and paracentesis in Malignant Ascites, sponsored by Wuhan YZY Biopharma Co., Ltd.. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Wuhan YZY Biopharma Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 43 studies in Ascites with a site in China — 14 open to participants now, 16 under way, 1 of them phase 3. Ascites · China.

Enrollment
4th of 37
312 · median 48
Started
2024
with 6 others
Phase 3
4 of 43
none open now
Primary completion
2025-08
later than 3 of 15 live
Registered
31st of 43
by date
Lead sponsor
2 of 43
Wuhan YZY Biopharma Co., Ltd.

Among the 43 studies in Ascites with a site in China, this one is the 4th largest by enrollment of the 37 interventional ones that give a count, is one of 7 that started in 2024, is one of 4 in phase 3, reaches primary completion later than 3 of the 15 other live ones, and was the 31st registered.

Ascites

248 studies on the registry are indexed under Ascites; 57 are open to participants now.

Browse Ascites studies →

Open to participants now

14 of the 43 studies in Ascites with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 40 Ascites studies recruiting now, 21 (53%) set no upper age limit and 12 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Ascites with a site in China, or all of them as a file.
02

Study summary

A Randomized, Controlled, Multi-Center Phase III Clinical Study to Compare the Efficacy and Safety of Recombinant Anti-EpCAM and Anti-CD3 Human-Mouse Chimeric Bispecific Antibody (M701) for Intraperitoneal Injection to Paracentesis alone in Patients with Malignant Ascites Caused by Advanced Epithelial Solid Tumors.

Read the detailed description

The phase III study is a controlled, open-label trial designed to assess the effectiveness and safety of M701 intra-peritoneal infusion for controlling malignant ascites in patients with Malignant Ascites Caused by Advanced Epithelial Solid Tumors who are also receiving systemic therapy.

A total of 306 patients with malignant ascites caused by Malignant Ascites Caused by Advanced Epithelial Solid Tumors will be randomly assigned to two treatment arms in a 2:1 ratio. These patients must have experienced disease progression or intolerance after receiving at least two lines of systemic therapy.

Both treatment arms will receive the systemic therapy as per the investigator's instructions. The test arm will receive paracentesis and intra-peritoneal infusion of M701, while the control arm will receive paracentesis alone.

The primary endpoint of the study is the puncture-free survival, which evaluates the efficacy of M701 in controlling malignant ascites. Secondary endpoints include the overall survival (OS),Time to next puncture (TTNP), Patient-reported outcome (PRO) score, 6-month survival rate,1-month and 2-month puncture-free survival rate, safety profiles,and Anti-m701 antibody (ADA) and Neutralizing antibody (NAb).

03

Conditions studied

  • Malignant Ascites

Browse trials for

Keywords

  • M701
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and voluntarily sign the written form;
  2. Age ≥18 years and ≤75 years;
  3. or pathologically confirmed epithelial malignant solid tumors,including: advanced gastric cancer and colorectal cancer that have failed at least two (treatment failure is defined as progression after treatment or intolerance after treatment); or platinum-resistant (platinum-efractory) dvanced ovarian cancer;
  4. Pathologically or clinically diagnosed with malignant ascites, and treatment for malignant ascites is required as judged by the investigator; B-mode ultrasound confirms that the volume of ascites is moderate or above (moderate or above ascites is defined as the maximum depth of ascites by B-mode ultrasound in supine position is ≥ 4.5 cm, or the actual amount of ascites drained is ≥ 1 L;
  5. The time interval between the last anti-tumor treatment and Randomization should meet the following time intervals:

    1. Intraperitoneal therapy: The time from the most recent intraperitoneal infusion therapy to randomization should be ≥ 2 weeks;
    2. Systemic treatment: No washout required;
    3. AEs should have recovered to Grade ≤ 1 from previous treatment (except for other adverse reactions (such as alopecia) that do not affect the safety evaluation of the drug as judged by the investigator according to V5.0);
  6. PS score of 0 to 2;
  7. An expected survival of ≥ 8 weeks;
  8. Organ functions must meet the following criteria:

    1. Hematology: (ANC) ≥ 1.5 × 10\^9/L, ≥90 ×10\^9/L, ≥ 85 g/L, and lymphocyte percentage ≥ 10%;
    2. Liver function: total ≤ 1.5 × (ULN), (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN (AST and ALT ≤ 5 × ULN are allowed in case of liver );
    3. Serum albumin ≥ 28 g/L;
    4. Renal function: serum creatinine ≤ 1.5 × ULN.
  9. Female subjects of should have a negative pregnancy test at screening; all female subjects of childbearing potential and male subjects should take adequate measures throughout the treatment period and within 6 months after the end of the study.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a known history of allergy to M701 or its components; patients with a known history of allergy to macromolecular ntibody drugs or a history of specific allergic reactions (asthma, rubella, and eczematous dermatitis);
  2. Have previously used M701, or have used antibody drugs targeting EpCAM and/or CD3 within 4 months before the first dose;
  3. Patients with central nervous system (CNS) resulting in clinical symptoms or requiring therapeutic intervention; patients with previously treated can be enrolled if they are asymptomatic and have stable disease as indicated by imaging examination ≥ 4 weeks before the first dose and do not require or anticonvulsant therapy;
  4. Have undergone major surgery within 4 weeks prior to randomization or plan to undergo major surgery during the study(excluding exploratory surgery);
  5. New or concurrent infection within 14 days prior to randomization that has not been controlled to clinical stability;
  6. Patients with severe respiratory diseases at screening, leading to respiratory failure or those judged by the investigator to be unsuitable for enrollment;
  7. Patients with active diseases (e.g., inflammatory bowel disease,idiopathic thrombocytopenic purpura, lupus rythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, and rheumatoid arthritis), but patients with the following conditions are allowed to be screened: type I diabetes;hypothyroidism that can be controlled by replacement therapy only; skin diseases that do not require systemic treatment (e.g., vitiligo, psoriasis, and alopecia);
  8. Patients with severe cardiovascular and cerebrovascular diseases at screening,including cardiac insufficiency ( Class III-IV); acute cardiovascular and cerebrovascular events (acute myocardial infarction, acute cerebral infarction,unstable angina, cerebral hemorrhage, etc.) orundergone vascular stenting within 6 months(Coronary artery stent implantation, intracranial artery stent implantation,etc.) or pulmonary embolism within the past 6 months; or venous thrombotic diseases such as venous thrombosis in lower limb within the past month;
  9. Patients with complete intestinal obstruction within 30 days prior to Randomization,or those diagnosed with subileus but judged by the investigator as unsuitable for participating in the study based on their symptoms, signs, etc., or those have severe gastrointestinal disease such as gastric/intestinal perforation;
  10. Unable to drain the ascites completely due to objective reasons (including ascites septation) or complicated with chylous ascites;
  11. Portal vein embolism or portal hypertension confirmed by examinations;
  12. Patients with active chronic [such as positive hepatitis B surface antigen (HBsAg) and/or positive hepatitis B core antibody (HBcAb), and HBV DNA ≥2000 IU/mL or HBV DNA ≥5000cps/mL], active [such as positive hepatitis C virus (HCV) antibody and HCV RNA ≥ lower limit of detection], positive (HIV) antibody, or active syphilis infection (positive syphilis-specific antibody and positive syphilis non-specific antibody);
  13. Patients with concurrent pleural effusion and clinical symptoms such as chest tightness and dyspnea, who have received clinical intervention or require clinical intervention as assessed by the investigator; or those with concurrent moderate to severe symptomatic pericardial effusion;
  14. Pregnant or lactating women;
  15. History of definitive neurological or mental disorders that, per the investigator's judgment, may affect the cognitive function or compliance of the patient, including unstable epilepsy, dementia, and schizophrenia;
  16. Other conditions that the investigator considers unsuitable for participating in this clinical study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
312 participants (actual)

Study arms

  • Experimental
    M701 group

    M701 will be administered via intra-peritoneal infusion following sufficient drainage of malignant ascites. The treatment regimen consists of a leading dose of 50μg on Day 1, followed by three infusions of the full dose of 400 μg M701 on Days 4, 11, and 18. If well tolerated, patients will continue to receive M701 infusions every 2 weeks as maintenance treatment.Additionally, these patients will receive systemic therapy as determined by the investigator.

    Drug: M701

  • Active comparator
    Control group

    Patients in the control group will undergo paracentesis on Day 1 and Day 18. If necessary, they may receive additional paracentesis during this period. Additionally, these patients will receive systemic therapy as determined by the investigator.

    Procedure: paracentesis

Interventions

  • DrugM701

    Intra-peritoneal infusion of M701 in experimental group (M701 group\_

  • Procedureparacentesis

    Puncture and Draiange of ascites from the peritoneal cavity in both experimental group and control group

06

What researchers measure

Primary outcomes

  1. PuFS

    Defined as the time from the end of C1V4 ascites drainage to the next drainage (based on the time of puncture) or the time of death is recorded as the PuFS.

    Time frame: Time from the end of drainage of ascites at C1V4 to the start of the next drainage or death (up to 6 months)

Secondary outcomes

  1. OS

    Time from randomization to death from any cause

    Time frame: Time from randomization to death from any cause (up to 6 months).

Other outcomes

  1. TTNP

    Time from the end of drainage of C1V4 ascites to the beginning of the next drainage (as the time of drainage)

    Time frame: Time from the end of drainage of ascites at C1V4 to the start of the next drainage (up to 6 months

  2. The score of quality of life

    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 V3.0) was used to evaluate the quality of life of the subjects. This questionnaire is a 30 item instrument meant to assess some of the different aspects that define the quality of life of cancer patients. For the first 28 questions, the score is from 1-4, the lower score represents the better quality. For the last 2 quesionts, the score is from 1-7, the higher score represents the better health and quality of life. Deterioration in each module score of Patient-Reported Outcome (PRO): defined as a decrease of ≥ 5 points from baseline in each module score of the EORTC QLQ-C30 questionnaire.

    Time frame: Time from randomization to the start of the next drainage or death (up to 6 months)

  3. 1-month and 2-month PuFS rates

    1-month and 2-month PuFS rates

    Time frame: 1st and 2nd month from the end of drainage of C1V4 ascites

  4. 6-month survival rate

    6-month survival rate

    Time frame: 6th month from randomization

  5. Likert Scale

    Symptoms and signs assessed using a Likert scale

    Time frame: Time from randomization to the start of the next drainage or death (up to 6 months)

  6. Three-dimensional Volume of Ascites

    Ascites volume assessed via abdominal CT scan

    Time frame: Time from randomization to the start of the next drainage or death (up to 6 months)

  7. Immunogenicity Analysis

    The positive rate of Anti-Drug Antibody (ADA) and Neutralizing antibody (Nab) in the serum and ascites during the study

    Time frame: Time from randomization to the start of the next drainage or death (up to 6 months)

  8. Population Pharmacokinetics and Exposure-Response Analysis

    * Construct the population pharmacokinetic (PopPK) model of M701 in ascites and serum of patients with malignant ascites; * Evaluate the effects of intrinsic/extrinsic factors on the pharmacokinetic (PK) characteristics of M701 (if data permit); * Evaluate the relationship between M701 exposure and pharmacodynamic (PD)/efficacy indicators in patients with malignant ascites, including the number of EpCAM-positive cells in ascites, the number of CD45-positive cells in ascites, serum IL-6 level, puncture-free survival (PuFS), and overall survival (OS); * Evaluate the relationship between M701 exposure and safety indicators in patients with malignant ascites, including intestinal obstruction, abdominal infection, treatment-emergent adverse events (TEAE), and treatment-related adverse events (TRAE).

    Time frame: Time from randomization to the start of the next drainage or death (up to 6 months)

  9. Indidence of Adverse events

    Incidence of Treatment-Emergent Adverse Events, ≥grade 3 Treatment-Emergent Adverse Events, Serious Adverse Events and Treatment-Related Adverse Events.

    Time frame: From the time of first dosing (Day 1) until one month after the end of treatment

  10. Exploratory Endpoint Analysis

    1. Based on the PKS data, descriptive statistical analysis will be performed on drug concentrations in blood and ascites, including mean, standard deviation (SD), coefficient of variation (CV), median, minimum (Min), maximum (Max), geometric mean (GM), geometric standard deviation (GSD), and geometric coefficient of variation (GCV). 2. PD indicators (serum cytokines, relevant cells and cytokines in ascites) as well as their changes relative to baseline will be statistically described according to sample collection time points.

    Time frame: Time from randomization to the start of the next drainage or death (up to 6 months)

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Aug 2025, 16 months.

Of 13 phase 3 interventional studies under Ascites, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 49. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2024
First posted
May 29, 2024
StartActual
Mar 25, 2024
Primary completionActual
Aug 22, 2025
CompletionEst.
Dec 12, 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06432296
Lead sponsor
Wuhan YZY Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
May 29, 2024
Start date
Mar 25, 2024
Primary completion
Aug 22, 2025
Completion
Dec 12, 2026 (estimated)
Last update
Aug 20, 2026

Study contacts

Jianming Xu, MD
principal investigator · The First Medical Center of Chinese PLA General Hospital
Yanqiao zhang, PhD
principal investigator · The Second Affiliated Hospital of Harbin Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion